PURPOSE: Surgery and systemic chemotherapy offer modest benefit to @entity1 with recurrent @entity463 multiforme. These @entity5 are associated with rapid growth and progressive @entity16 . Radiosurgery offers a rational alternative treatment, delivering intensive local therapy. A pilot protocol to treat recurrent @entity463 was developed using fractionated stereotactic radiosurgery with concurrent intravenous (i.v.) Taxol as a radiation sensitizer. METHODS AND MATERIALS: The treatment outcome was analyzed in 14 @entity1 with recurrent @entity463 treated with fractionated stereotactic radiosurgery and concurrent Taxol. Median @entity5 volume was 15.7 cc and @entity1 received a mean radiation dose of 6.2 Gy at 90% isodose line, 4 times weekly. The median dose of @entity1311 was 120 mg/m2. RESULTS: The median survival was 14.2 months, 1-year survival was 50%. CONCLUSIONS: Survival for this small group of @entity1 was similar to or better than historical controls or @entity1 treated with single-fraction radiosurgery alone. This data should stimulate the investigation of both fractionated radiosurgery and the development of radiation sensitizers to further enhance treatment.

Fractionated stereotactic radiosurgery and concurrent @entity1311 in recurrent XXXX multiforme: a preliminary report.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological deterioration'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['Taxol'] @entity463 :: ('MESH:D005909', 'Disease') :: ['glioblastoma']
@entity463 :: (MESH:D005909,Disease) :: ['glioblastoma']
